Drug Profile
Research programme: ROR gamma T inhibitors - Orca Pharmaceuticals/AstraZeneca
Alternative Names: ROR inhibitors - Orca Pharmaceuticals/AstraZeneca; RORγt inhibitors - Orca Pharmaceuticals/AstraZenecaLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Orca Pharmaceuticals
- Developer AstraZeneca; Orca Pharmaceuticals
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom (PO)
- 25 Feb 2015 Orca Pharmaceuticals collaborates with AstraZeneca for the development of ROR gamma antagonists
- 25 Feb 2015 Early research in Autoimmune disorders in United Kingdom (PO)